Subscribe to receive I-Tech AB press releases, financial reports and other bulletins

* indicates required

Please select all the ways you would like to hear from I-Tech AB:


You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here.


Press releases (ENG)

The share issue in I-Tech AB (publ) for listing on First North was over-subscribed

I-Tech AB (publ) ("I-Tech" or "the Company") has completed the share issue to public and institutional investors in Sweden to subscribe for 1 875 000 shares in the Company of approximately SEK 38.5 Million ("Offering"). The interest in participating in the share issue has been strong and overall, the share issue was subscribed to approximately…

Read more

I-Tech AB carries out a share issue of MSEK 44.1 ahead of listing on Nasdaq First North

The Board of I-Tech AB ("I-Tech" or "The Company") has decided to carry out an equity issue of up to 2 150 000 shares and apply for listing of the Company's shares on Nasdaq First North. 

Read more

I-Tech AB signs deal for largest ever Selektope® order with Chugoku Marine Paints

I-Tech AB, the Swedish developer of the bio-repellent antifouling ingredient Selektope®, has signed a significant supply agreement with one of the industry’s leading paint manufacturers representing the largest ever single order of the technology to-date. This deal represents yet another significant milestone for Selektope®, confirming the central position of coatings containing the ingredient in the…

Read more

I-Tech AB strengthens Selektope® supply chain with strategic acquisition

Swedish bio-technology company I-Tech AB has today announced the strategic acquisition of manufacturing process technology and IP, for the production of medetomidine, from Cambrex Corporation (NYSE: CBM). The transaction consolidates the supply chain and improves I-Tech’s industrial capabilities. I-Tech AB has registered and patented medetomidine as a marine antifouling agent and is offering the active…

Read more